Insulin: 10–20 units with 25–50 g of glucose to prevent hypoglycemia
Hydragogue: Loop diuretics and acetazolamide increase urinary K+ losses in extremely severe hyperkalemia in moderately decreased kidney function
SGLT2i: Lower hyperkalemia incidence of 3.27% with canagliflozin in T2DM or CKD patients vs. 4.19% with placebo
Patiromer: Brings K+ <5.1 mmol/L in 71% of hyperkalemia veterans with HF, diabetes, or CKD
Patiromer: Also enables patients with resistant hypertension and CKD to continue spironolactone with less hyperkalemia
ZS-9: Reduces K+ >1 mmol/L after 38 h in 41.7% of patients
Cresp 2
Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients
